Evidence map›Paper›PMID 36483199›Full record

ArticleFrontiers in microbiology2022

Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections.

Yun Shan Goh, Siew-Wai Fong, Pei Xiang Hor, Siti Naqiah Amrun, Cheryl Yi-Pin Lee, Barnaby Edward Young, Po Ying Chia, Paul A Tambyah, Shirin Kalimuddin, Surinder Pada and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Yun Shan GohASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Siew-Wai FongASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Pei Xiang HorASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Siti Naqiah AmrunASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Cheryl Yi-Pin LeeASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Barnaby Edward YoungNational Centre for Infectious Diseases, Singapore, Singapore.
Po Ying ChiaDepartment of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
Paul A TambyahDepartment of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
Shirin KalimuddinDepartment of Infectious Diseases, Singapore General Hospital, Singapore, Singapore.
Surinder PadaDivision of Infectious Diseases, Ng Teng Fong Hospital, Singapore, Singapore.
Seow-Yen TanDepartment of Infectious Diseases, Changi General Hospital, Singapore, Singapore.
Louisa Jin SunAlexandra Hospital, Singapore, Singapore.
Mark I-Cheng ChenNational Centre for Infectious Diseases, Singapore, Singapore.
Yee-Sin LeoNational Centre for Infectious Diseases, Singapore, Singapore.
David C LyeNational Centre for Infectious Diseases, Singapore, Singapore.
Lisa F P NgASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Laurent ReniaASTAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Agency for Science, Technology and Research · SGNational University of Singapore · SGAlexandra Hospital · SGChangi General Hospital · SGNanyang Technological University · SGNg Teng Fong General Hospital · SGSingapore General Hospital · SGTan Tock Seng Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19 has a wide disease spectrum ranging from asymptomatic to severe. While humoral immune responses are critical in preventing infection, the immune mechanisms leading to severe disease, and the identification of biomarkers of disease progression and/or resolution of the infection remains to be determined. Methods: Plasma samples were obtained from infections during the initial wave of ancestral wildtype SARS-CoV-2 and from vaccine breakthrough infections during the wave of Delta variant, up to six months post infection. The spike-specific antibody profiles were compared across different severity groups and timepoints. Results: We found an association between spike-specific IgM, IgA and IgG and disease severity in unvaccinated infected individuals. In addition to strong IgG1 and IgG3 response, patients with severe disease develop a robust IgG2 and IgG4 response. A comparison of the ratio of IgG1 and IgG3 to IgG2 and IgG4 showed that disease progression is associated with a smaller ratio in both the initial wave of WT and the vaccine breakthrough Delta infections. Time-course analysis revealed that smaller (IgG1 and IgG3)/(IgG2 and IgG4) ratio is associated with disease progression, while the reverse associates with clinical recovery. Discussion: While each IgG subclass is associated with disease severity, the balance within the four IgG subclasses may affect disease outcome. Acute disease progression or infection resolution is associated with a specific immunological phenotype that is conserved in both the initial wave of WT and the vaccine breakthrough Delta infections.

Indexed as

antibodiesCOVID-19cytokinesIgG subclassesrecoverySARS-CoV-2severityS protein

Identifiers

PMID36483199
PMCPMC9723332
OpenAlexW4311027580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.